Market Place
Sourcing Support
FDA Grants Rare Pediatric Disease Designation To Omeros’ Zaltenibart
24 Oct 2024 //
BUSINESSWIRE
Omeros Corporation Reports Second Quarter 2024 Financial Results
07 Aug 2024 //
BUSINESSWIRE
Omeros To Announce Q2 Results On August 7, 2024
05 Aug 2024 //
BUSINESSWIRE
Omeros Announces Webcast Details for Annual Meeting of Shareholders
04 Jun 2024 //
BUSINESSWIRE
Omeros Strengthens Balance Sheet, Extends Debt Maturity To 2028
03 Jun 2024 //
BUSINESSWIRE
Omeros Corporation Reports First Quarter 2024 Financial Results
15 May 2024 //
BUSINESSWIRE
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
10 May 2024 //
BUSINESSWIRE
Omeros Upcoming Presentations At EHA 2024 Congress
09 May 2024 //
BUSINESSWIRE
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results
27 Mar 2024 //
BUSINESSWIRE
Omeros Announces Presentation Detailing Narsoplimab Compassionate Use
20 Feb 2024 //
BUSINESSWIRE
Omeros Announces Additional Royalty Monetization with DRI Healthcare Trust
01 Feb 2024 //
BUSINESSWIRE
Omeros Corporation Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Omeros to Announce Third Quarter Financial Results on November 9, 2023
06 Nov 2023 //
BUSINESSWIRE
Omeros Announces Online Publication in Advance of ASH Annual Meeting
03 Nov 2023 //
BUSINESSWIRE
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
02 Nov 2023 //
BUSINESSWIRE
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
19 Oct 2023 //
BUSINESSWIRE
Omeros terminates development of kidney disease therapy after study failure
17 Oct 2023 //
REUTERS
Omeros Provides Update on Analysis of Phase 3 Trial of Narsoplimab
16 Oct 2023 //
BUSINESSWIRE
Omeros Corporation Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
Omeros to Announce Second Quarter Financial Results on Morning of August 9, 2023
04 Aug 2023 //
BUSINESSWIRE
Why Shares of Omeros Dropped on Monday
12 Jun 2023 //
FOOL
Omeros Announces Availability On Its Website Of Materials
12 Jun 2023 //
PRESS RELEASE
Omeros Announces Late-Breaking Presentation of OMS906 Data at EHA
01 Jun 2023 //
BUSINESSWIRE
Omeros Corporation Reports First Quarter 2023 Financial Results
09 May 2023 //
BUSINESSWIRE
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
04 May 2023 //
BUSINESSWIRE
Omeros Awarded $6.69 Million Grant for its OMS527 Addiction Program
10 Apr 2023 //
BUSINESSWIRE
Omeros saddles up for 2nd charge at transplant drug approval
14 Mar 2023 //
FIERCE BIOTECH
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
13 Mar 2023 //
BUSINESSWIRE
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
10 Mar 2023 //
BUSINESSWIRE
Omeros to Announce Fourth Quarter and Year End Financial Results on March 13
07 Mar 2023 //
BUSINESSWIRE
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
06 Feb 2023 //
BUSINESSWIRE
Omeros Corporation Reports Third Quarter 2022 Financial Results
09 Nov 2022 //
BUSINESSWIRE
Omeros Receives Decision from FDA on Dispute Resolution Request for Narsoplimab
08 Nov 2022 //
BUSINESSWIRE
Omeros Corporation to Announce Q3 Financial Results on November 9, 2022
04 Nov 2022 //
BUSINESSWIRE
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
03 Nov 2022 //
BUSINESSWIRE
Omeros Corporation Announces Royalty Monetization Transaction with DRI
03 Oct 2022 //
BIOSPACE
Omeros reports clinical data from I-SPY COVID Trial of narsoplimab
16 Sep 2022 //
CLINICALTRIALSARENA
Omeros Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients
16 Sep 2022 //
BUSINESSWIRE
Omeros` Hail Mary throw for blood clot med delayed at FDA
18 Aug 2022 //
FIERCEBIOTECH
Omeros Corp Receives Interim Response From FDA On Formal Dispute Resolution
17 Aug 2022 //
PRESS RELEASE
Omeros Corporation Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
Omeros Corp to Announce Second Quarter Financial Results
04 Aug 2022 //
BUSINESSWIRE
FDA Grants ODD to Omeros’ OMS906 for Paroxysmal Nocturnal Hemoglobinuria
29 Jul 2022 //
BUSINESSWIRE
Omeros Announces Webcast Details for Annual Meeting of Shareholders
15 Jun 2022 //
BUSINESSWIRE
Omeros Corporation Reports First Quarter 2022 Financial Results
10 May 2022 //
BUSINESSWIRE
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
04 May 2022 //
BUSINESSWIRE
Omeros Announces Journal of Clinical Oncology Publication
20 Apr 2022 //
BUSINESSWIRE
Omeros Corporation to Announce Q4 and Year-end Financial Results on March 1
24 Feb 2022 //
BUSINESSWIRE
Omeros Submits Response to FDA Regarding the BLA for Narsoplimab
19 Jan 2022 //
BUSINESSWIRE
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
23 Dec 2021 //
BUSINESSWIRE
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
23 Dec 2021 //
BUSINESSWIRE
A Seattle biotech offloads lead eye drug in deal valued at $1B+
03 Dec 2021 //
ENDPTS
Omeros offloads Omidria in pivot to focus on complement drug pipeline
02 Dec 2021 //
BENZINGA
Omeros Corporation Reports Third Quarter 2021 Financial Results
09 Nov 2021 //
BUSINESSWIRE
FDA rejects Omeros drug over difficulties estimating its effect
19 Oct 2021 //
FIERCEBIOTECH
Omeros slips 11% on JPMorgan downgrade, analyst anticipates CRL
08 Oct 2021 //
SEEKINGALPHA
Omeros` rough start to October continues as shares down ~24%
08 Oct 2021 //
SEEKINGALPHA
Omeros stock craters as FDA cites deficiencies in application for HSCT-TMA drug
02 Oct 2021 //
ENDPTS
Omeros Corporation Reports Second Quarter 2021 Financial Results
09 Aug 2021 //
BUSINESSWIRE
Omeros Corporation to Announce Second Quarter Financial Result
04 Aug 2021 //
BUSINESSWIRE
